Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

319
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
319
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

770
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
770
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

722
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
722

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Delivering Quadruple Therapy for Heart Failure With Reduced Ejection Fraction in a Customizable Polypill: The COMBO-HF-X Pilot Randomized Trial.

JACC. Heart failure·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Global heart·2026
Same author

Provider Preferences About a Polypill for Heart Failure With Reduced Ejection Fraction: Development of a Multicenter Physician Survey Containing a Discrete Choice Experiment.

Journal of cardiac failure - intersections·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

European heart journal·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Journal of the American College of Cardiology·2026

相关实验视频

Updated: Jan 15, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

为心力衰竭患者开发一个多层次的多药丸实施包,用于减少喷射分数的心力衰竭患者.

Justin C Chen1, Colette DeJong2, Mansi Agarwal3

  • 1Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.

JACC. Advances
|October 9, 2025
PubMed
概括

一种针对心力衰竭的新多药药策略,可降低排气分数 (HFrEF),可以改善患者的治疗结果. 这项研究确定了关键因素,并开发了一个实施包,以指导其在HFrEF护理中的使用.

关键词:
固定剂量组合药丸是固定的.心力衰竭与减少的喷射分数心力衰竭实施地图的实施地图.实施科学 实施科学多种类型的药丸.

更多相关视频

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

相关实验视频

Last Updated: Jan 15, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

科学领域:

  • 心脏病学 心脏病学
  • 实施科学 实施科学
  • 医疗保健服务研究 医疗服务研究

背景情况:

  • 含有针对心力衰竭的指导方针导向医学疗法的多药丸,具有减少喷射率 (HFrEF),有望改善患者的治疗结果.
  • 然而,影响HFrEF基于多药药的策略成功实施的因素在很大程度上是未知的.

研究的目的:

  • 确定影响HFrEF基于多种药物的策略的决定因素.
  • 设计一个多层次的实施捆绑HFrEF的多种类型.
  • 为了说明这个捆绑如何提高患者的结果.

主要方法:

  • 在两个机构中,与患者 (N=9) 和提供者 (N=22) 进行了一项融合的并行混合方法研究.
  • 实施研究综合框架v2.0指导了对基于多种药物的HFrEF护理的数据收集.
  • 使用匹配工具和机制映射来开发实施捆绑.

主要成果:

  • 利益相关者采访中出现了四个主要主题,包括HFrEF护理的现状,对创新的认识,评估创新的适当性和能力建设.
  • 这些主题为开发7个领域的多层次HFrEF多药剂实施包提供了信息.
  • 一个指向的非循环图说明了捆绑对患者结果的潜在影响.

结论:

  • 开发了一个多层次的HFrEF多实行包.
  • 该包为改善HFrEF护理提供了一个框架,特别是在治疗不足的人群中.
  • 进一步定制捆绑可以优化其全球应用.